A*Star Report issue

Government Phase 1 Phase 2 Phase 3

Organization Overview

First Clinical Trial
2015
NCT02774993
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

A*Star | A*STAR Infectious Diseases Labs | D3 (Drug Discovery and Development), Biomedical Sciences Institute | D3, Senior Medical Director | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | E-Star BioTech, LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Tuberculosis (Phase 2)

Tuberculosis, Pulmonary (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 13